论文部分内容阅读
目的探讨应用口服普萘洛尔治疗婴幼儿眼睑眶周血管瘤的方法和临床疗效。方法回顾性分析婴幼儿眼睑眶周血管瘤25例25眼,服药至6-12个月,分别在服药后第4、12、24周观察血管瘤色泽和高度等外观变化以及通过眼部彩超或眼眶MRI检查进行瘤体的生物学测量,比较不同时间点的瘤体容积百分比变化,观察随访至停药后6个月,对疗效和安全性进行评价。结果 20例(80%)患儿于服药后24h瘤体颜色较前变淡,质地变软,大小未变。服药6个月后整体容积百分比平均降低了65.3%,至随访终末,有效率达到100%,其中基本治愈和治愈比例达到87.2%。结论口服普萘洛尔对于具有治疗指征的眼睑眶周血管瘤不失为一种安全有效的治疗方法。
Objective To investigate the method and clinical efficacy of oral propranolol in the treatment of infantile eyelid periorbital hemangiomas. Methods A retrospective analysis of 25 cases of eyelid periorbital hemangiomas in 25 children, taking 6 to 12 months, respectively, at 4,12,24 weeks after taking hematoma color and height were observed changes in appearance and by eye or ultrasonography Orbital MRI examination of the biological measurements of the tumor, compared the tumor volume percentage changes at different time points, the observation was followed up to 6 months after withdrawal, the efficacy and safety evaluation. Results In 20 cases (80%), the color of the tumor became lighter after 24 hours and the texture became soft and the size was unchanged. After six months of taking the medication, the volume percentage decreased by 65.3% on average, and the effective rate reached 100% at the end of the follow-up. The basic cure rate and cure rate reached 87.2%. Conclusion Oral propranolol may be a safe and effective treatment for eyelid periorbital hemangiomas with indications for treatment.